Puma Biotechnology (PBYI) EBIT (2017 - 2025)
Historic EBIT for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $9.6 million.
- Puma Biotechnology's EBIT fell 5664.21% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.6 million, marking a year-over-year increase of 357.73%. This contributed to the annual value of $31.0 million for FY2024, which is 512.87% down from last year.
- Latest data reveals that Puma Biotechnology reported EBIT of $9.6 million as of Q3 2025, which was down 5664.21% from $6.6 million recorded in Q2 2025.
- Puma Biotechnology's 5-year EBIT high stood at $22.1 million for Q3 2024, and its period low was -$16.6 million during Q2 2021.
- Over the past 5 years, Puma Biotechnology's median EBIT value was $4.9 million (recorded in 2023), while the average stood at $5.3 million.
- Its EBIT has fluctuated over the past 5 years, first crashed by 33331.46% in 2021, then skyrocketed by 209125.25% in 2022.
- Quarter analysis of 5 years shows Puma Biotechnology's EBIT stood at -$503000.0 in 2021, then soared by 2091.25% to $10.0 million in 2022, then soared by 47.74% to $14.8 million in 2023, then dropped by 9.68% to $13.4 million in 2024, then decreased by 28.37% to $9.6 million in 2025.
- Its EBIT was $9.6 million in Q3 2025, compared to $6.6 million in Q2 2025 and $4.0 million in Q1 2025.